Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Recruiting

Phase 1

Phase 2

Pidnarulex & CemiplimabTesting the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT07147231

Conditions

Metastatic Colorectal Adenocarcinoma

Refractory Colorectal Adenocarcinoma

Stage III Colorectal Cancer AJCC v8

Stage IV Colorectal Cancer AJCC v8

Unresectable Colorectal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Cemiplimab

Computed Tomography

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-24. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-04-20.